These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 19458008)

  • 21. Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection.
    Summa V; Petrocchi A; Bonelli F; Crescenzi B; Donghi M; Ferrara M; Fiore F; Gardelli C; Gonzalez Paz O; Hazuda DJ; Jones P; Kinzel O; Laufer R; Monteagudo E; Muraglia E; Nizi E; Orvieto F; Pace P; Pescatore G; Scarpelli R; Stillmock K; Witmer MV; Rowley M
    J Med Chem; 2008 Sep; 51(18):5843-55. PubMed ID: 18763751
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Transmission of integrase strand-transfer inhibitor multidrug-resistant HIV-1: case report and response to raltegravir-containing antiretroviral therapy.
    Young B; Fransen S; Greenberg KS; Thomas A; Martens S; St Clair M; Petropoulos CJ; Ha B
    Antivir Ther; 2011; 16(2):253-6. PubMed ID: 21447875
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment with suboptimal doses of raltegravir leads to aberrant HIV-1 integrations.
    Varadarajan J; McWilliams MJ; Hughes SH
    Proc Natl Acad Sci U S A; 2013 Sep; 110(36):14747-52. PubMed ID: 23959861
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment with integrase inhibitor suggests a new interpretation of HIV RNA decay curves that reveals a subset of cells with slow integration.
    Cardozo EF; Andrade A; Mellors JW; Kuritzkes DR; Perelson AS; Ribeiro RM
    PLoS Pathog; 2017 Jul; 13(7):e1006478. PubMed ID: 28678879
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [How proviral DNA is integrated into the host cell DNA and how this process can be inhibited].
    Mirambeau G
    Enferm Infecc Microbiol Clin; 2008 Nov; 26 Suppl 12():11-6. PubMed ID: 19572420
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Microbial Natural Product Alternariol 5-O-Methyl Ether Inhibits HIV-1 Integration by Blocking Nuclear Import of the Pre-Integration Complex.
    Ding J; Zhao J; Yang Z; Ma L; Mi Z; Wu Y; Guo J; Zhou J; Li X; Guo Y; Peng Z; Wei T; Yu H; Zhang L; Ge M; Cen S
    Viruses; 2017 May; 9(5):. PubMed ID: 28489061
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of the HIV-1 genetic background and HIV-1 population size on the evolution of raltegravir resistance.
    Fun A; Leitner T; Vandekerckhove L; Däumer M; Thielen A; Buchholz B; Hoepelman AIM; Gisolf EH; Schipper PJ; Wensing AMJ; Nijhuis M
    Retrovirology; 2018 Jan; 15(1):1. PubMed ID: 29304821
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of raltegravir on the total and unintegrated proviral HIV DNA during raltegravir-based HAART.
    Nicastri E; Tommasi C; Abbate I; Bonora S; Tempestilli M; Bellagamba R; Viscione M; Rozera G; Gallo AL; Ivanovic J; Amendola A; Pucillo L; Di Perri G; Capobianchi MR; Narciso P
    Antivir Ther; 2011; 16(6):797-803. PubMed ID: 21900711
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeting the HIV integration process in antiviral therapy.
    McNeely M; Christ F; Thys W; Debyser Z
    J HIV Ther; 2008 Dec; 13(4):83-92. PubMed ID: 19418658
    [No Abstract]   [Full Text] [Related]  

  • 30. Raltegravir: molecular basis of its mechanism of action.
    Mouscadet JF; Tchertanov L
    Eur J Med Res; 2009 Nov; 14 Suppl 3(Suppl 3):5-16. PubMed ID: 19959411
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Selection of diverse and clinically relevant integrase inhibitor-resistant human immunodeficiency virus type 1 mutants.
    Kobayashi M; Nakahara K; Seki T; Miki S; Kawauchi S; Suyama A; Wakasa-Morimoto C; Kodama M; Endoh T; Oosugi E; Matsushita Y; Murai H; Fujishita T; Yoshinaga T; Garvey E; Foster S; Underwood M; Johns B; Sato A; Fujiwara T
    Antiviral Res; 2008 Nov; 80(2):213-22. PubMed ID: 18625269
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The HIV-1 integrase genotype strongly predicts raltegravir susceptibility but not viral fitness of primary virus isolates.
    Buzón MJ; Dalmau J; Puertas MC; Puig J; Clotet B; Martinez-Picado J
    AIDS; 2010 Jan; 24(1):17-25. PubMed ID: 19770695
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Integrase inhibitors effective against human T-cell leukemia virus type 1.
    Seegulam ME; Ratner L
    Antimicrob Agents Chemother; 2011 May; 55(5):2011-7. PubMed ID: 21343468
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of raltegravir on 2-long terminal repeat circle junctions in HIV type 1 viremic and aviremic patients.
    Bona R; Baroncelli S; D'Ettorre G; Andreotti M; Ceccarelli G; Filati P; Leone P; Blasi M; Michelini Z; Galluzzo CM; Mallano A; Vullo V; Cara A
    AIDS Res Hum Retroviruses; 2013 Oct; 29(10):1365-9. PubMed ID: 23802629
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vitro resistance selections using elvitegravir, raltegravir, and two metabolites of elvitegravir M1 and M4.
    Margot NA; Hluhanich RM; Jones GS; Andreatta KN; Tsiang M; McColl DJ; White KL; Miller MD
    Antiviral Res; 2012 Feb; 93(2):288-296. PubMed ID: 22197635
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Resistance to inhibitors of the human immunodeficiency virus type 1 integration.
    Hazuda DJ
    Braz J Infect Dis; 2010; 14(5):513-8. PubMed ID: 21221483
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Raltegravir (MK-0518): an integrase inhibitor for the treatment of HIV-1.
    Evering TH; Markowitz M
    Drugs Today (Barc); 2007 Dec; 43(12):865-77. PubMed ID: 18174972
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Integrated HIV DNA accumulates prior to treatment while episomal HIV DNA records ongoing transmission afterwards.
    Murray JM; McBride K; Boesecke C; Bailey M; Amin J; Suzuki K; Baker D; Zaunders JJ; Emery S; Cooper DA; Koelsch KK; Kelleher AD;
    AIDS; 2012 Mar; 26(5):543-50. PubMed ID: 22410637
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Biochemical screening assays to identify HIV-1 integrase inhibitors.
    Clynhens M; Smets A; Vereycken I; Van Loock M; Clayton R; Meersseman G; Goethals O
    Methods Mol Biol; 2013; 1030():25-36. PubMed ID: 23821258
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mutations associated with failure of raltegravir treatment affect integrase sensitivity to the inhibitor in vitro.
    Malet I; Delelis O; Valantin MA; Montes B; Soulie C; Wirden M; Tchertanov L; Peytavin G; Reynes J; Mouscadet JF; Katlama C; Calvez V; Marcelin AG
    Antimicrob Agents Chemother; 2008 Apr; 52(4):1351-8. PubMed ID: 18227187
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.